Allergic asthma is a disease that impacts the lives of millions and is created by critical intersections of clinical, environmental, biologic, and genetic factors. Allergen exposure is essential to the development of allergic asthma, but not all allergens associate with asthma. One allergen central to the development of allergic asthma, especially in children, is Alternaria, a common mold. A critical feature of Alternaria differentiating it from more benign allergens is protease activity. The proteases in Alternaria increase its biological activity by disrupting epithelial cell tight junctions, activating epithelial cells, and increasing lung inflammation. There are endogenous inhibitors of proteases, including SERine Protease INhibitors (Serpins) and Stefin protease inhibitors. These inhibitors are strongly upregulated with Alternaria exposure. The Central Hypothesis of this application is that Alternaria proteases are essential to Alternaria acting as an asthmagen by directly targeting the epithelium but these effects are modulated by Alternaria-induced host antiproteases. We will utilize proteomics, in vitro assays, and murine models of Alternaria-induced lung inflammation to assess the interaction of the epithelium and host antiproteases with Alternaria proteases and determine their impact on the development of allergic asthma.
Alternaria is a protease containing allergic pathogen central to the development of allergic asthma. This application investigates the interaction of Alternaria proteases with the host protease defenses in the pathogenesis of asthma. The results may lead to both primary prevention of asthma and novel asthma treatment options.
|Addison, Kenneth J; Morse, John; Robichaud, Annette et al. (2017) A Novelin vivoSystem to Test Bronchodilators. J Infect Pulm Dis 3:|
|Polley, D J; Mihara, K; Ramachandran, R et al. (2017) Cockroach allergen serine proteinases: Isolation, sequencing and signalling via proteinase-activated receptor-2. Clin Exp Allergy 47:946-960|
|Boitano, Scott; Hoffman, Justin; Flynn, Andrea N et al. (2015) The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo. Br J Pharmacol 172:4535-4545|
|Sherwood, Cara L; Daines, Michael O; Price, Theodore J et al. (2014) A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance. Am J Physiol Cell Physiol 307:C718-26|
|Boitano, Scott; Hoffman, Justin; Tillu, Dipti V et al. (2014) Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering. PLoS One 9:e99140|
|Flynn, Andrea N; Hoffman, Justin; Tillu, Dipti V et al. (2013) Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. FASEB J 27:1498-510|
|Boitano, Scott; Flynn, Andrea N; Sherwood, Cara L et al. (2011) Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2. Am J Physiol Lung Cell Mol Physiol 300:L605-14|
|Muralidhar, Akshay; Borbon, Ivan A; Esharif, Dyadin M et al. (2011) Pulmonary function and pathology in hydroxypropyl-beta-cyclodextin-treated and untreated Npc1?/? mice. Mol Genet Metab 103:142-7|
|Sivaprasad, Umasundari; Askew, David J; Ericksen, Mark B et al. (2011) A nonredundant role for mouse Serpinb3a in the induction of mucus production in asthma. J Allergy Clin Immunol 127:254-61, 261.e1-6|